Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. HALO today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 12:40 p.m. PT / 3:40 p.m. ET. The virtual conference will be held from January 11-14, 2021.

An audio-only direct link of the presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 30 days following the event. To access the link, please visit Halozyme's website approximately 10 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE^® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE^® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE^®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

SOURCE Halozyme Therapeutics, Inc.